Renalytix AI plc

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in New York, NY.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs

Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care

Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management

Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 World Changing Ideas Awards. "We are honored to be recognized by Fast Company for our Pandemic Response efforts," said Sara Barrington of Kantaro COVID-SeroKlir measures the presence and precise level of IgG antibodies against the receptor-binding domain and the full-length spike protein — the same type of antibodies produced as part of the immune response to COVID-19 virus exposure or generated by a vaccine.

Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards

Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. The contract, offered through the General Services Administration, covers laboratory testing services that can be provided through more than 140 U.S. government departments, agencies.

Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services

Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021

KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)

Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease

RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform

Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings

Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions

Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes

Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Company's Employee Share Purchase Plan (“the ESPP”), new 17,652 ordinary shares of £0.0025 each in the capital of the Company (“the Ordinary Shares”) have been issued to settle the purchase of 8,826 American Depositary Shares, each representing two Ordinary Shares (“ADSs”) by employees who participated in the ESPP. Further details in relation to the ESPP were contained in the Company's announcement of 2 September 2020.

Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights

Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease

The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it will report its financial results for the six and three months ended December 31, 2020 on Tuesday, March 2, 2021.

RenalytixAI to announce Financial Results for six and three months ended December 31, 2020

Renalytix AI continues to soar. The story of AI-enhanced kidney diagnostics is attractive, albeit the addressable market isn't huge.

Renalytix AI: Time To Grow Into Its Valuation

Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations

Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

Renalytix AI (RNLX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Renalytix AI (RNLX) Catches Eye: Stock Jumps 7%

First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs

Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be presenting at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.

RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 2, 2020 /PRNewswire/ --The National Kidney Foundation (NKF) announced today a partnership with Renalytix AI (NASDAQ:RNLX) to improve kidney disease diagnosis and assessment in the earliest stage of the disease that will ultimately guide clinical interventions and treatments...

NKF and RenalytixAI Partner to Improve Management of Early Stage Kidney Disease

AIM ImmunoTech Inc

AnPac Bio-Medical Science Co

AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and COVID-19. AIM ImmunoTech is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.

News for Renalytix AI plc Stock (RNLX)